JP2019537599A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537599A5
JP2019537599A5 JP2019523739A JP2019523739A JP2019537599A5 JP 2019537599 A5 JP2019537599 A5 JP 2019537599A5 JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019523739 A JP2019523739 A JP 2019523739A JP 2019537599 A5 JP2019537599 A5 JP 2019537599A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537599A (ja
JP7097880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/059234 external-priority patent/WO2018085247A1/en
Publication of JP2019537599A publication Critical patent/JP2019537599A/ja
Publication of JP2019537599A5 publication Critical patent/JP2019537599A5/ja
Application granted granted Critical
Publication of JP7097880B2 publication Critical patent/JP7097880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523739A 2016-11-01 2017-10-31 Malt1分解のための化合物 Active JP7097880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416066P 2016-11-01 2016-11-01
US62/416,066 2016-11-01
PCT/US2017/059234 WO2018085247A1 (en) 2016-11-01 2017-10-31 Compounds for malt1 degradation

Publications (3)

Publication Number Publication Date
JP2019537599A JP2019537599A (ja) 2019-12-26
JP2019537599A5 true JP2019537599A5 (enExample) 2020-12-10
JP7097880B2 JP7097880B2 (ja) 2022-07-08

Family

ID=62077048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523739A Active JP7097880B2 (ja) 2016-11-01 2017-10-31 Malt1分解のための化合物

Country Status (4)

Country Link
US (1) US10689366B2 (enExample)
EP (1) EP3535254A4 (enExample)
JP (1) JP7097880B2 (enExample)
WO (1) WO2018085247A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
EP3374361A1 (en) * 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
WO2019197468A1 (en) 2018-04-12 2019-10-17 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CN118344338A (zh) 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
JP7349450B2 (ja) 2018-04-25 2023-09-22 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としての新規ヘテロアリール-トリアゾール化合物及びヘテロアリール-テトラゾール化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019242625A1 (zh) * 2018-06-20 2019-12-26 上海科技大学 制备来那度胺衍生物的方法
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2020263989A1 (en) 2019-06-24 2020-12-30 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
JP7691973B2 (ja) 2019-07-23 2025-06-12 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としての新規なヘテロアリール-トリアゾール化合物
CN117567338A (zh) 2019-10-09 2024-02-20 拜耳公司 作为农药的新的杂芳基三唑化合物
CN116194453A (zh) * 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
WO2021217036A1 (en) * 2020-04-23 2021-10-28 Salem Aliasger K Gper proteolytic targeting chimeras
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
EP4163280A4 (en) 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PRODUCING A HETEROCYCLIC COMPOUND
AU2021293907A1 (en) * 2020-06-17 2023-01-19 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス,インコーポレーテッド がんを治療する材料及び方法
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CA3205512A1 (en) * 2021-01-29 2022-08-04 Ksenya Cohen Katsenelson Molecular glue screening assays and methods for practicing same
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
JP2025503727A (ja) * 2022-01-18 2025-02-04 オーリジーン オンコロジー リミテッド Malt-1阻害剤としての置換二環式複素環関連出願の相互参照 この出願は、2022年1月18日に提出されたインド仮特許出願第202241002859号に対する優先権を主張する。この仮出願の全内容は、参照により本明細書に組み込まれる。
TW202340198A (zh) * 2022-01-28 2023-10-16 大陸商上海齊魯製藥研究中心有限公司 靶向malt1的蛋白降解化合物、包含其的醫藥組合物及其用途
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
US20250163066A1 (en) * 2022-02-25 2025-05-22 Tegid Therapeutics, Inc. PROTACs of MALT1
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic glutarimide-modified cervalon-binding agents
CN118047654A (zh) * 2023-12-29 2024-05-17 黑龙江立科新材料有限公司 从芳胺出发制备芳基卤化物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020029419A (ko) * 1999-07-07 2002-04-18 다비드 에 질레스 퀴나졸린 유도체
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
JP5479105B2 (ja) 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
US8993758B2 (en) * 2010-11-22 2015-03-31 Board Of Regents Of The University Of Nebraska Substituted quinoxalines and uses thereof
US20150201001A1 (en) 2014-01-13 2015-07-16 Facebook, Inc. Systems and methods for priority-based digital content downloading
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
WO2015187827A1 (en) 2014-06-03 2015-12-10 The Trustees Of The University Of Pennsylvania Novel effective antiviral compounds and methods using same
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US10806737B2 (en) * 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides

Similar Documents

Publication Publication Date Title
JP2020511454A5 (enExample)
JP2013518107A5 (enExample)
JP2014508804A5 (enExample)
JP2018522866A5 (enExample)
JP2019510832A5 (enExample)
JP2019524883A5 (enExample)
CA2582734A1 (en) Dimeric small molecule potentiators of apoptosis
JP2017511360A5 (enExample)
JP2009535352A5 (enExample)
JP2014510774A5 (enExample)
RU2018137389A (ru) Гетероциклические амиды, полезные в качестве модуляторов
JP2010501584A5 (enExample)
JP2018519245A5 (enExample)
JP2018516238A5 (enExample)
JP2008512490A5 (enExample)
KR20170081228A (ko) 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
JP2014503574A5 (enExample)
JP2017528498A5 (enExample)
JP2009536620A5 (enExample)
JP2018531987A5 (enExample)
JP2015506348A5 (enExample)
JP2009531403A5 (enExample)
JP2010510237A5 (enExample)
JP2016506962A5 (enExample)
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции